95 related articles for article (PubMed ID: 22893261)
1. A vasodilating β1 blocker celiprolol inhibits muscular release of uric acid precursor in patients with essential hypertension.
Mizuta E; Utami SB; Ohtahara A; Endo S; Mishima M; Hasegawa A; Yamada K; Kato M; Yamamoto K; Ogino K; Ninomiya H; Miyazaki S; Hamada T; Taniguchi SI; Cheng J; Hisatome I
Horm Metab Res; 2013 Jan; 45(1):69-73. PubMed ID: 22893261
[TBL] [Abstract][Full Text] [Related]
2. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers.
Ohtahara A; Hisatome I; Yamamoto Y; Furuse M; Sonoyama K; Furuse Y; Hamada T; Katoh M; Watanabe M; Kinugawa T; Ogino K; Igawa O; Shimomura T; Murakami F; Yamamoto T; Shigemasa C
J Hypertens; 2001 Mar; 19(3 Pt 2):575-82. PubMed ID: 11327632
[TBL] [Abstract][Full Text] [Related]
3. Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension.
Saner H; Seiler A; Mahler F
Arzneimittelforschung; 1995 Jul; 45(7):790-5. PubMed ID: 8573224
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of hypertension with a new beta blocker-diuretic combination under long-term control].
Hoffmann H; Hoffmann W
Wien Med Wochenschr; 1985 Mar; 135(5):127-34. PubMed ID: 2859703
[TBL] [Abstract][Full Text] [Related]
5. Adding beta-2 agonism does not improve beta-1 blockade exercise responses in hypertensives.
Rueckert PA; Slane PR; Hanson P
Med Sci Sports Exerc; 1994 Aug; 26(8):945-50. PubMed ID: 7968427
[TBL] [Abstract][Full Text] [Related]
6. Celiprolol reduces oxidative stress and attenuates left ventricular remodeling induced by hypoxic stress in mice.
Nishioka S; Yoshioka T; Nomura A; Kato R; Miyamura M; Okada Y; Ishizaka N; Matsumura Y; Hayashi T
Hypertens Res; 2013 Nov; 36(11):934-9. PubMed ID: 23784509
[TBL] [Abstract][Full Text] [Related]
7. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the antihypertensive effects of celiprolol and enalapril.
Ghiringhelli S; Cozzi E; Tsialtas D
J Int Med Res; 1988; 16 Suppl 1():73A-79A. PubMed ID: 2906019
[TBL] [Abstract][Full Text] [Related]
9. The effects of celiprolol on serum concentrations of proinflammatory cytokines in hypertensive (SHR) and normotensive (WKY) rats.
Andrzejczak D; Górska D
Pharmacol Rep; 2014 Feb; 66(1):68-73. PubMed ID: 24905309
[TBL] [Abstract][Full Text] [Related]
10. [Use of selective long-acting beta-blocker with vasodilating activity celiprolol in patients with essential hypertension].
Podzolkov VI; Mozharova LG
Kardiologiia; 2002; 42(10):22-6. PubMed ID: 12494052
[TBL] [Abstract][Full Text] [Related]
11. Vasodilating effects of celiprolol in patients with peripheral obliterative arterial disease.
Diehm C
J Int Med Res; 1988; 16 Suppl 1():34A-38A. PubMed ID: 2975611
[TBL] [Abstract][Full Text] [Related]
12. Lipid profile improvement following celiprolol.
Herrmann JM; von Heyman F; Freischütz G
J Int Med Res; 1988; 16 Suppl 1():39A-46A. PubMed ID: 2906016
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of beta-blocker with intrinsic sympathomimetic activity on stress-induced cardiac dysfunction in rats.
Ishikura F; Takano Y; Ueyama T
J Cardiol; 2012 Dec; 60(6):470-4. PubMed ID: 22898333
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
Erley CM; Klass M; Krämer D; Berger E; Heyne N; Braun N; Wolf S; Risler T
Int J Clin Pharmacol Ther; 1996 Nov; 34(11):504-9. PubMed ID: 8937934
[TBL] [Abstract][Full Text] [Related]
15. [Uricosuric action of a new beta receptor blocker-diuretic drug combination].
Brandstetter G; Hoffmann H; Maderbacher H; Eslaminejad S
Acta Med Austriaca; 1986; 13(2):29-37. PubMed ID: 2876573
[TBL] [Abstract][Full Text] [Related]
16. Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol.
Vyssoulis GP; Kouremetis MT; Valiouli MA; Michaelides AP; Toutouzas PK
Cardiovasc Drugs Ther; 1995 Feb; 9(1):133-9. PubMed ID: 7786833
[TBL] [Abstract][Full Text] [Related]
17. Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.
Dunn CJ; Spencer CM
Drugs Aging; 1995 Nov; 7(5):394-411. PubMed ID: 8573993
[TBL] [Abstract][Full Text] [Related]
18. Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension.
Malminiemi K; Lahtela JT; Huupponen R
Int J Clin Pharmacol Ther; 1995 Mar; 33(3):156-63. PubMed ID: 7599914
[TBL] [Abstract][Full Text] [Related]
19. Effect of beta-blockade on baroreceptor and autonomic function in heart failure.
Sanderson JE; Yeung LY; Chan S; Tomlinson B; Kay R; Woo KS; Bernardi L
Clin Sci (Lond); 1999 Feb; 96(2):137-46. PubMed ID: 9918893
[TBL] [Abstract][Full Text] [Related]
20. beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes.
Hayashi T; Juliet PA; Miyazaki-Akita A; Funami J; Matsui-Hirai H; Fukatsu A; Iguchi A
Life Sci; 2007 Jan; 80(6):592-9. PubMed ID: 17141277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
